Phase I trial of mesencephalic astrocyte-derived neurotrophic factor (MANF) in patients with Parkinson's disease.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 14 May 2015
At a glance
- Drugs Mesencephalic astrocyte-derived neurotrophic factor (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- 14 May 2015 This trial in Parkinson's disease appears to have been withdrawn prior to enrolment, as Amarantus BioScience Holdings is targeting retinitis pigmentosa for first-in-man studies of mesencephalic astrocyte-derived growth factor, as reported in a media release.
- 09 Jun 2011 New trial record